A new economic analysis has been rolled out by Amgen of Repatha’s Fourier, which is an outcome study that proved to be unsuccessful in the early stages to impress the market at the time of disclosure this year. The PCSK9 drug is said to be cost-effective at the rate of $9,669 every year, or even less than that, which makes it almost $5,000 less on its price. That’s a devaluation of 31% following typical discounts. However, Amgen states that it’s still extremely expensive under assessments conducted earlier, which also included one assessment that had been publishes earlier this week, with a reduction of 71%, in the Journal of the American Medical Association. It is suggested by Amgen that this new study is distinctive, as it includes real-world data, involving rates of cardiovascular events other than clinical trials.
However, a Fourier result was faced with a criticism of the amount of patients that were being treated in order to prevent one stroke or heart-attack and its cost in comparison with the cost of statins. Amgen has expressed that, in patients who are at high risk, the number is relatively reduced. In an interview that was conducted earlier this year, Amgen’s VP of global health economics, Martin Zagari mentioned that with stations there is a 1% annual risk of events and the risk of people who get Repatha is 11%,12%,13% consequently higher.
He further stated that the story they are trying to make people understand is that Repatha patients compared to statin patients the prevention of events is relatively same by 10 times. The data of today reflects the difference. After trying various clinical scenarios and making the use of a combination of real world data as well as Fourier data it was detected by the researchers that in a typical patient of the United States who is suffering from atherosclerosis, Repatha costs at $9,669. SVP of global value, access and policy, Joshua Of man confirmed in a statement that this study guarantees the clinical advantages and the value of economy of providing Repatha to the suitable patients who are at high risk, mainly in patients who have experienced a stroke or heart attack regardless of maximally-tolerated therapies of statin. He further stated that currently, the actual price in the market given by the payers after discounts are said be in line to the range that is value based in this study.